Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method
Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna · 2026
Read Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method by Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13286212.txt.
Description
Dorra Abdelmalek and colleagues hunt borrowed drugs for cancers driven by the normal form of a growth receptor in a 2026 computer study. Most approved blockers aim at mutated versions of the EGFR receptor, leaving patients whose tumors run on the standard form with few choices. Since a sister receptor shares both shape and cancer roles, its approved blockers became the hunting ground.
Five candidate drugs from that shelf all docked into the standard receptor's fuel pocket in flexible fitting runs. One, coded D4, gripped best, touching two anchor points that govern the pocket's shape. A long motion simulation kept the pair stable, and energy sums backed the strong grip with hard numbers. Bench proof still lies ahead, but the authors name D4 as the lead worth testing first against this stubborn target.
Catalog record
| CREATOR | Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91104 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |